[HTML][HTML] CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
CDK4/6 inhibitors are oral agents inhibiting key molecules of the cell cycle regulation. In
patients with endocrine receptor positive (ER+), human epidermal growth factor receptor 2 …
patients with endocrine receptor positive (ER+), human epidermal growth factor receptor 2 …
Financial Toxicity Questionnaire (FIT): Development and Validation of the Italian Version (FITALY) in Head and Neck Cancer patients
D Smussi, C Conti, L Lorini, D Mattavelli, R Levaggi… - 2024 - researchsquare.com
Background. Financial toxicity from cancer treatments is rising as an important patient-
reported outcome. Its relevance was first assessed in the context of privately financed …
reported outcome. Its relevance was first assessed in the context of privately financed …